Abbott Will Grow Zemplar Sales With Oral Formulation, Predialysis Use
This article was originally published in The Pink Sheet Daily
Executive Summary
An NDA filing for oral Zemplar in predialysis chronic kidney disease patients is slated for this summer. Amgen's Sensipar will have "no effect" on the Zemplar I.V. business, Abbott says.
You may also be interested in...
Pre-Dialysis Kidney Disease Market Heats Up With Oral Zemplar NDA, Hectorol Launch
Bone Care International's launch of the first vitamin D compound approved for secondary hyperparathyroidism in pre-dialysis patients (Hectorol) coincides with Abbott's NDA filing for Zemplar capsules.
Pre-Dialysis Kidney Disease Market Heats Up With Oral Zemplar NDA, Hectorol Launch
Bone Care International's launch of the first vitamin D compound approved for secondary hyperparathyroidism in pre-dialysis patients (Hectorol) coincides with Abbott's NDA filing for Zemplar capsules.
Amgen Sensipar Approved; Target U.S. Market At Least 300,000 Patients
Cinacalcet is indicated for the treatment of hyperparathyroidism associated with kidney disease and hypercalcemia in parathyroid cancer patients.